Loading…
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $60M | $-98M | $-114M | $-101M | -55.4% | 115.1% | - |
| 2024 | $28M | $-76M | $-94M | $-85M | 45.0% | 264.5% | - |
| 2023 | $8M | $-74M | $-84M | $-85M | 71.6% | - | - |
| 2021 | $0M | $-32M | $-34M | $-30M | -1931.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 7.63 | 27.81 | 59.81 |
| Cost Of Revenue | 0 | 18.28 | 27.45 | 35.60 |
| Gross Profit | 0 | -10.65 | 0.36 | 24.21 |
| Operating Expense | 32.71 | 69.77 | 85.42 | 130.59 |
| Operating Income | -32.71 | -80.42 | -85.06 | -106.38 |
| EBITDA | -32.33 | -73.74 | -76.31 | -97.98 |
| EBIT | -32.75 | -78.59 | -87.87 | -105.94 |
| Pretax Income | -33.91 | -84.22 | -94.10 | -113.68 |
| Tax Provision | 0.19 | 0.01 | 0.02 | 0.14 |
| Net Income | -34.10 | -84.24 | -94.12 | -113.81 |
| Net Income Common Stockholders | -34.10 | -86.74 | -100.84 | -126.14 |
| Total Expenses | 32.71 | 88.05 | 112.88 | 166.19 |
| Interest Expense | 1.17 | 5.63 | 6.23 | 7.73 |
| Interest Income | 0 | 0 | 0 | 3.20 |
| Research And Development | 18.81 | 15.76 | 15.49 | 15.65 |
| Selling General And Administration | 13.90 | 54.01 | 69.94 | 114.94 |
| Normalized EBITDA | -32.33 | -73.74 | -76.31 | -95.33 |
| Normalized Income | -34.10 | -84.24 | -94.12 | -111.72 |
| Basic EPS | -1.71 | -4.36 | -5.07 | -5.13 |
| Diluted EPS | -1.71 | -4.36 | -5.07 | -5.13 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | -0.56 |
| Tax Rate For Calcs | 0.27 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | 0 | 0 | 0 | -2.65 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | -2.65 |
| Net Income From Continuing Operation Net Minority Interest | -34.10 | -84.24 | -94.12 | -113.81 |
| Reconciled Depreciation | 0.42 | 4.86 | 11.56 | 7.97 |
| Reconciled Cost Of Revenue | 0 | 18.28 | 27.45 | 35.60 |
| Net Interest Income | -1.17 | -5.63 | -6.23 | -4.54 |
| Net Income From Continuing And Discontinued Operation | -34.10 | -84.24 | -94.12 | -113.81 |
| Total Operating Income As Reported | -32.71 | -80.42 | -85.06 | -106.38 |
| Diluted Average Shares | 19.89 | 19.89 | 19.89 | 24.58 |
| Basic Average Shares | 19.89 | 19.89 | 19.89 | 24.58 |
| Diluted NI Availto Com Stockholders | -34.10 | -86.74 | -100.84 | -126.14 |
| Preferred Stock Dividends | 0 | 2.50 | 6.72 | 12.32 |
| Minority Interests | 0 | 0 | 0.69 | 0 |
| Net Income Including Noncontrolling Interests | -34.10 | -84.24 | -94.12 | -113.81 |
| Net Income Continuous Operations | -34.10 | -84.24 | -94.12 | -113.81 |
| Other Income Expense | -0.04 | 1.83 | -2.80 | -2.77 |
| Other Non Operating Income Expenses | -0.04 | 1.83 | -2.80 | -0.12 |
| Gain On Sale Of Security | 0 | 0 | 0 | -2.65 |
| Net Non Operating Interest Income Expense | -1.17 | -5.63 | -6.23 | -4.54 |
| Interest Expense Non Operating | 1.17 | 5.63 | 6.23 | 7.73 |
| Interest Income Non Operating | 0 | 0 | 0 | 3.20 |
| Selling And Marketing Expense | 13.90 | 34.92 | 40.68 | 0 |
| Operating Revenue | 0 | 7.63 | 27.81 | 59.81 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd.this co. | KMTS | $1.1B | - | 3.95 | -55.4% | -6.60 |
| CONMED Corporation | CNMD | $1.2B | 25.12 | 1.14 | 4.6% | 11.20 |
| UroGen Pharma Ltd. | URGN | $1.1B | - | -10.70 | 145.5% | -9.20 |
| Jade Biosciences, Inc. | JBIO | $1.1B | - | 3.31 | -38.3% | -6.74 |
| InnovAge Holding Corp. | INNV | $1.1B |
| 161.40 |
| 4.27 |
| -11.5% |
| 25.32 |
| Zenas BioPharma, Inc. | ZBIO | $1.1B | - | - | -156.0% | -3.15 |
| EyePoint, Inc. | EYPT | $1.1B | - | 32.47 | -75.8% | -4.95 |
| Pacira BioSciences, Inc. | PCRX | $1.1B | 149.91 | 1.52 | 1.0% | 10.73 |
| CareDx, Inc. | CDNA | $1.1B | - | 3.49 | -7.0% | -124.58 |
| Peer Median | - | 149.91 | 3.31 | -9.3% | -4.05 | |